The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study (Pre-fALS)

This study is currently recruiting participants.

See

Contacts and Locations

Verified June 2017 by Michael Benatar, University of Miami

Sponsor:

Collaborator:

ALS Association

Information provided by (Responsible Party):

Michael Benatar, University of Miami

ClinicalTrials.gov Identifier:

NCT00317616

First received: April 24, 2006

Last updated: June 8, 2017

Last verified: June 2017

History of Changes

Purpose

Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. The investigators aim to recruit unaffected (healthy) people from familial ALS (fALS) pedigrees in which a known genetic mutation associated with ALS has been identified; for this study, a fALS pedigree is one with two biologically related individuals who have or have had ALS and/or FTD. Individuals who may be at genetic risk for ALS and who belong to families with at least one affected family member who has tested positive for a known ALS genetic mutation may also be eligible to participate. Our goal is to study the pre-symptomatic phase, onset and progression of ALS and to learn more about genetic and environmental factors that put people at risk for developing ALS.

Condition
Amyotrophic Lateral Sclerosis


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study

Resource links provided by NLM:

Genetics Home Reference related topics: amyotrophic lateral sclerosis

MedlinePlus related topics: Amyotrophic Lateral Sclerosis

Genetic and Rare Diseases Information Center resources: Amyotrophic Lateral Sclerosis

U.S. FDA Resources

Further study details as provided by Michael Benatar, University of Miami:

Primary Outcome Measures:

Risk Factors for Progression to familial ALS [ Time Frame: Years ]

Biospecimen Retention: Samples With DNA

Serum, Plasma, CSF, DNA, Urine, Cell lines


Estimated Enrollment:	500
Study Start Date:	April 2006
Estimated Study Completion Date:	December 2027
Estimated Primary Completion Date:	December 2027 (Final data collection date for primary outcome measure)

Detailed Description:

Healthy individuals from fALS families with a known genetic mutation will be included in this study. We encourage people who have previously undergone genetic testing and were found to carry the mutation that affects their family as well as those who do not know their genetic status to contact us. Those who wish to participate and to learn the results of genetic testing, may do so after undergoing genetic counseling. It is also possible to participate without learning the results of genetic testing. Participants eligible to complete study visits will travel to Miami (at our expense) approximately every 12-24 months for a period of 10 years or longer and will perform various biomarker procedures. Between visits, participants will complete phone calls about their health.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Healthy individuals who harbor a mutation in a gene associated with ALS.

Criteria

Inclusion Criteria

A member of a family in which a mutation in a gene associated with ALS has been identified.
No symptoms to suggest the presence of ALS (i.e. study participants must currently be healthy).
Having at least 50% probability of carrying an ALS associated gene mutation based on family pedigree.
Willingness to undergo genetic testing, with the option of whether or not to learn the results.
Willingness and availability to travel to Miami for a few days approximately every 12 to 24 months to complete biomarker procedures (e.g, MRI, blood draws, spinal tab/lumbar puncture, cognitive testing)

Exclusion Criteria

Diagnosis of ALS
Any condition or situation which, in the PI's opinion, could confound the biomarker data or may interfere with the individual's participation and compliance with the study protocol, including but not limited to neurological, psychological and/or medical conditions.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00317616

Contacts


Contact: Eliana M Reyes	1-888-413-9315	fals@med.miami.edu
Contact: Danielle Dauphin	1-888-413-9315

Locations


United States, Florida
University of Miami	Recruiting
Miami, Florida, United States, 33136
Contact: Eliana Reyes 888-413-9315 fals@med.miami.edu
Contact: Danielle Dauphin

Sponsors and Collaborators

University of Miami

ALS Association

Investigators


Principal Investigator:	Michael G Benatar, MD, PhD.	University of Miami

More Information


Responsible Party:	Michael Benatar, MBChB, MS, DPhil, University of Miami
ClinicalTrials.gov Identifier:	NCT00317616 History of Changes
Other Study ID Numbers:	Pre-fALS
Study First Received:	April 24, 2006
Last Updated:	June 8, 2017

Keywords provided by Michael Benatar, University of Miami:


FALS SOD1 familial genetic testing genetic counseling ALS	C9ORF72 TARDBP VCP FUS PFN1

Additional relevant MeSH terms:


Sclerosis Motor Neuron Disease Amyotrophic Lateral Sclerosis Pathologic Processes Neurodegenerative Diseases Nervous System Diseases	Neuromuscular Diseases Spinal Cord Diseases Central Nervous System Diseases TDP-43 Proteinopathies Proteostasis Deficiencies Metabolic Diseases

ClinicalTrials.gov processed this record on June 22, 2017

To Top